Perspectives of multi-OMICS analysis from blood, saliva and tumor tissue in patients with oral cavity carcinomas with regard to diagnostics, therapy and recurrence detection.

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

DRKS

Registry ID

DRKS00030492

Enrollment

400

Registered

2022-12-19

Start date

2023-01-01

Completion date

Unknown

Last updated

2025-04-07

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

C00 C01 C02 C03 C04 C05 C06

Interventions

Group 1: Preoperative: - Informing and inclusion in the study. - Blood collection and saliva sample - EDTA blood: exome / germline analysis - Plasma: miRNA analysis - Saliva: miRNA analysis Intraope

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Inclusion criteria

Inclusion criteria: - Newly diagnosed tumors of the oral cavity - Indication for surgical therapy

Exclusion criteria

Exclusion criteria: - Simultaneous malignancies - Patient refusal to participate in the study - No indication for surgical therapy

Design outcomes

Primary

Measure	Time frame
OMICS signatures 3,6 and 12 month after operation	—

Secondary

Measure	Time frame
Survival after 5 years	—

Countries

France, Germany, Spain, United Kingdom

Contacts

Public ContactMarcel Ebeling

Bundeswehrkrankenhaus Ulm

Marcelebeling@bundeswehr.org0731 171035806

Outcome results

None listed

Source: DRKS (via WHO ICTRP) · Data processed: Feb 4, 2026